- 中國臨床腫瘤學會（CSCO）惡性血液病診療指南·2020
- 中國臨床腫瘤學會指南工作委員會
- 311字
- 2020-08-26 18:35:11
1.3 預后
預后分組參考G?kbuget等 ［5］發表的危險度分組標準（表1-1）。細胞遺傳學分組參考NCCN 2019（表1-2）。
ALL診斷確立后，應根據具體分型、預后分組采用規范化的分層治療策略，以取得最佳治療效果。
表1-1 成人ALL預后分組
表1-1 成人ALL預后分組（續表）
注：CR.完全緩解；MRD.微小殘留病；？.可能有意義，但尚未達成共識
表1-2 NCCN2019年B-ALL細胞遺傳學危險度分組
參考文獻
［1］ DE HAAS V, ISMAILA N, ADVANI A, et al. Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline. J Clin Oncol, 2019 Jan 20, 37 (3): 239-253.
［2］ NCCN Clinical Practice Guidelines in Oncology-Acute Lymphoblastic Leukemia (2019 Version 2) [DB/OL]. http: //www. nccn. org.
［3］ BENE MC, CASTOLDI G, KNAPP W, et al. Proposals for the immunological classi fi cation of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia, 1995, 9 (10): 1783-1786.
［4］ ARBER DA, ORAZI A, HASSERJIAN R, et al. The 2016 revision to the World Health Organization classi fi cation of myeloid neoplasms and acute leukemia. Blood, 2016, 127: 2391-2405.
［5］ G?KBUGET N, HOELZER D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol, 2009, 46 (1): 64-75.